Shares of Gilead fell after a key drug from the company failed to improve survival in a late-stage trial on patients with advanced lung cancer.
The drugmaker said it will discuss the results with regulators and identify whether certain lung cancer patients may still benefit from the drug, called Trodelvy.
The results are a blow to Gilead, which is working to become a power player in the cancer space.